Thalia Therapeutics

What it does

Thalia Therapeutics is a British biotechnology company developing RNA-based therapeutics and proprietary delivery technologies. Its platform, Nuvec®, uses amorphous silica nanoparticles with an irregular surface structure to trap and protect RNA, enabling multi-RNA loading, flexible targeting, and potential oral delivery. The company's pipeline includes a dual-target cardiovascular siRNA programme for atherosclerotic cardiovascular disease (ASCVD) and a clinical-stage microRNA therapeutic candidate, miRisten, for Acute Myeloid Leukaemia, acquired through the acquisition of Sanmirna Therapeutics alongside a €3.1 million raise.

Who it is for

Thalia Therapeutics targets patients with serious diseases in oncology and cardiovascular disease who have significant unmet medical needs. Its RNA-based therapies aim to address conditions such as Acute Myeloid Leukaemia and ASCVD. The company also positions its delivery technology as a platform for partners, offering scalable and repeatable applications across multiple RNA modalities and indications.

Why it matters

RNA therapeutics hold transformative potential for treating disease, but effective delivery remains a key challenge. Thalia's Nuvec® technology aims to overcome this by enabling targeted delivery, high RNA loading, and the possibility of oral administration. By combining delivery innovation with a capital-efficient development strategy, the company seeks to generate high-quality clinical and preclinical data while creating partnering and licensing opportunities. The acquisition of Sanmirna and the miRisten candidate adds a clinical-stage asset to its portfolio, potentially accelerating its path to market.

Launch signal

Thalia Therapeutics announced the acquisition of Sanmirna Therapeutics alongside a €3.1 million raise, bringing the clinical-stage microRNA therapeutic miRisten for Acute Myeloid Leukaemia into its portfolio. This move signals the company's expansion and commitment to advancing RNA-based therapies. The company's website also lists news articles and press releases, though specific dates and details are limited in the available evidence.

Brand and naming

The name "Thalia" evokes the Greek muse of comedy and poetry, suggesting a creative and innovative approach to science. The full name "Thalia Therapeutics" clearly communicates its focus on therapeutic development. The brand positions itself as a British BioTech company with a strong emphasis on delivery innovation, using the proprietary Nuvec® technology as a key differentiator. The tagline "RNA-Based Medicines & Delivery Tech" succinctly captures its core business.